Intrabone Transplant of Cord Blood Stem Cells Establishes a Local Engraftment Store: A Functional PET/FDG Study

Table 1

Main patients’ characteristics.

Age	Gender	Disease	Disease status	HLA match	Overall number of infused donor cells (×10^7/kg)	Number of donor CD34^+ cells (×10^5/kg)	Time to PMN recovery (≥0.5 × 10^9/L), days	Time to PLT recovery (≥20 × 10^9/L), days	PLT count at day 100 (×10^9/kg)
66	M	nHL	Refractory	4/6	2.13	0.68	32	48	130
36	F	AML	2 CR	4/6	4.15	2.32	22	30	28
25	M	CML	Refractory	4/6	2.29	0.41	21	23	165
44	M	AML	2 CR	4/6	4.07	1.26	27	38	101
49	F	AML	1 CR (HR)	4/6	3.40	2.20	23	33	122
48	M	AML/HD	Secondary after HD	4/6	2.85	2.70	27	45	^†
47	M	AML	1 CR (HR)	4/6	2.00	1.69	18	38	111
42	M	ALL	Refractory	4/6	4.40	0.86	27	13	^†
34	M	HD	Refractory	4/6	3.49	1.96	24	42	124
37	M	ALL	Refractory	4/6	3.12	1.04	14	34	175
22	F	CML	Disease relapse	4/6	5.20	3.38	14	18	/
43	F	HD	Refractory	4/6	3.28	0.80	23	32	148
33	M	ALL	Refractory	4/6	3.45	1.14	23	26	77
49	F	AML	1 CR (HR)	4/6	3.87	2.67	22	35	155
50	M	AML	Refractory	4/6	2.74	0.53	29	44	100
58	M	nHL	Refractory	4/6	2.58	1.58	24	38	127
46	F	CML	Disease relapse	4/6	1.97	1.60	24	39	/
38	M	AML	2 CR	4/6	2.19	1.00	19	37	212
36	M	AML	Refractory	4/6	2.46	1.00	19	29	^†
56	M	CML	Refractory	4/6	2.90	1.67	19	34	118
58	M	PMF	Refractory	4/6	3.36	1.71	24	36	51

ALL: acute lymphatic leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; HD: Hodgkin’s disease; nHL: non-Hodgkin’s lymphoma; PMF: primary myelofibrosis; 1 CR: first complete remission; 2 CR: second complete remission; HR: high risk; PMN: polymorphonucleated cells; PLT: platelets; ^†Patient died.